Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MelaFind comes a step closer to the US market with FDA approvable letter

This article was originally published in Clinica

Executive Summary

Mela Sciences' troubled melanoma detection device MelaFind finally looks likely to reach the US market after the company received an approvable letter from the FDA. The company must now agree a protocol with the agency for a post-approval study in order to obtain final approval, as well as finalising physician and patient labelling, the package insert, user's guide and training programme.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT097926

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel